We are looking forward to participating in the Jefferies Global Healthcare Conference on June 4th in New York! Join CEO Mark McCamish, CSO Heba Nowyhed and CMO Julie Maltzman to learn more about exciting progress with ICVB-1042, a potentially best-in-class oncolytic virus which is currently being evaluated in its first-in-human Phase 1 trial for advanced solid tumors. #JefferiesHealthcare
IconOVir Bio
Biotechnology Research
San Diego, California 2,208 followers
Pushing the envelope: Our mission is to cure cancer and restore life to every patient everywhere
About us
IconOVir Bio is a preclinical-stage biotechnology company pioneering the next generation of oncolytic virus therapy to improve the treatment of patients with cancer. Our proprietary oncolytic virus platform is based on technology developed by scientific founder Clodagh O’Shea, Ph.D., of the Salk Institute. It is designed to address key limitations of first- and second-generation oncolytic viruses.
- Website
-
http://www.iconovir.com
External link for IconOVir Bio
- Industry
- Biotechnology Research
- Company size
- 11-50 employees
- Headquarters
- San Diego, California
- Type
- Privately Held
Locations
-
Primary
Get directions
4570 Executive Drive
Suite 350
San Diego, California 92121, US